Mercer Global Advisors Inc Denali Therapeutics Inc. Transaction History

Mercer Global Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $16,016 - $23,881	-731 Reduced 2.7%	26,299 $605,000
Q4 2022 Feb 08, 2023	BUY	$26.28 - $33.92 $21,575 - $27,848	821 Added 3.13%	27,030 $752,000
Q3 2022 Nov 15, 2022	BUY	$25.97 - $38.53 $60,925 - $90,391	2,346 Added 9.83%	26,209 $804,000
Q2 2022 Aug 10, 2022	BUY	$20.88 - $35.19 $19,794 - $33,360	948 Added 4.14%	23,863 $702,000
Q1 2022 May 10, 2022	BUY	$29.0 - $47.27 $161,327 - $262,963	5,563 Added 32.06%	22,915 $737,000
Q4 2021 Feb 04, 2022	SELL	$42.59 - $55.02 $92,888 - $119,998	-2,181 Reduced 11.17%	17,352 $774,000
Q3 2021 Nov 10, 2021	BUY	$48.48 - $78.23 $946,959 - $1.53 Million	19,533 New	19,533 $985,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Mercer Global Advisors Inc with notifications on news.